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Nephrotoxicity during Vancomycin
Therapy in Combination with
Piperacillin-Tazobactam or Cefepime
W. Cliff Rutter,a,b Jessica N. Cox,b Craig A. Martin,a,b Donna R. Burgess,a,b
David S. Burgessa
University of Kentucky College of Pharmacy, Lexington, Kentucky, USAa; University of Kentucky HealthCare,
Lexington, Kentucky, USAb
ABSTRACT Recent reports have demonstrated that vancomycin (VAN) may lead to
an increase in the incidence of acute kidney injury (AKI) when it is combined with
antipseudomonal beta-lactams. This study compared the incidence of AKI associated
with VAN plus piperacillin-tazobactam (TZP) or cefepime (FEP). This was a retrospec-
tive, matched cohort study that was conducted at an academic medical center be-
tween September 2010 and September 2014 and that included adult patients with-
out severe chronic or structural kidney disease, dialysis, pregnancy, cystic fibrosis, or
a hospital transfer receiving TZP-VAN or FEP-VAN for at least 48 h. The primary out-
come was the difference in the AKI incidence between the TZP-VAN and FEP-VAN
groups, evaluated using the risk, injury, failure, loss of kidney function, and end-
stage kidney disease (RIFLE) criteria. Patients in the two groups were matched on
the basis of age, sex, severity of illness, baseline creatinine clearance, hypotension,
number of nephrotoxicity risk factors, and intravenous contrast exposure. In total,
4,193 patients met all inclusion criteria (3,605 received TZP-VAN and 588 received
FEP-VAN). The unadjusted AKI incidence was 21.4% in patients receiving TZP-VAN,
whereas it was 12.6% in patients receiving FEP-VAN (P  0.001). After the patients
were matched, 1,633 patients receiving TZP-VAN and 578 patients receiving FEP-VAN
were evaluated. The AKI incidence remained higher in patients receiving TZP-VAN
than in those receiving FEP-VAN (21.4% versus 12.5%, P  0.0001). This trend re-
mained true for all classifications of the RIFLE criteria. After controlling for remaining
confounders, TZP-VAN therapy was associated with 2.18 times the odds of AKI than
FEP-VAN therapy (95% confidence interval, 1.64 to 2.94 times) in logistic regression.
AKI was significantly more common in patients receiving vancomycin in combination
with piperacillin-tazobactam than in those receiving vancomycin in combination with
cefepime. This finding reinforces the need for the judicious use of combination em-
pirical antimicrobial therapy.
KEYWORDS nephrotoxicity, piperacillin-tazobactam, adverse drug effects,
beta-lactams, cefepime, vancomycin
Nephrotoxicity is a well-established adverse effect of vancomycin (VAN) therapy.Risk factors for increased acute kidney injury (AKI) with vancomycin therapy
include concomitant administration with nephrotoxic agents, prolonged treatment
durations of greater than 7 days, daily vancomycin doses of 4 g or greater, and obesity
(1). The incidence of AKI with vancomycin therapy varies widely and is estimated to
range from 1.0 to 42% (2–4) Additionally, current guidelines for the treatment of
methicillin-resistant Staphylococcus aureus (MRSA) infections advocate the use of more
aggressive dosing to combat the increasing MICs associated with treatment failure (5).
The addition of an antipseudomonal beta-lactam agent, such as piperacillin-
tazobactam (TZP) or cefepime (FEP), is common in hospitalized patients. Beta-lactam
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antibiotics, primarily penicillin agents and early cephalosporins, have been associated
with acute interstitial nephritis (AIN) (6). Cases of cefepime-associated AIN have only
recently been reported (7). Recent literature suggests that the combination of VAN and
TZP is more nephrotoxic than VAN monotherapy and VAN combined with FEP (8–10).
However, the impact of TZP and VAN therapy may not be consistent among all patient
populations (11). No clear mechanism for the increase in AKI incidence in combination
therapy is known. The rate of AKI associated with TZP-VAN therapy in previous studies
ranged from 9.5% to 34.8% in a variety of patient populations (8–16).
The objective of this study was to evaluate the incidence of AKI with two commonly
prescribed antibiotic regimens in hospitalized patients, piperacillin-tazobactam with
vancomycin and cefepime with vancomycin.
RESULTS
Records for 10,141 patients were screened. After the exclusion criteria were applied
(Fig. 1), 4,193 patients were analyzed for all outcomes. Of 3,605 patients receiving
TZP-VAN who were evaluated in the unmatched analysis, 1,633 patients were matched
to 578 of 588 patients in the FEP-VAN group (98% of patients were matched). Of the
152 patients excluded due to an AKI occurring within 48 h after treatment initiation,
133 were from the TZP-VAN group (3.6% of the population treated with TZP-VAN) and
19 were from the FEP-VAN group (3.1% of the population treated with FEP-VAN). This
difference was not statistically significant (P  0.68), suggesting that the assumption
that AKIs occurring prior to 48 h of treatment are independent of drug selection is
correct.
At the baseline, the TZP-VAN group was older (51.5  16.0 versus 49.4  17.0 years,
P  0.006) and more likely to be male (60.4% versus 55.4%, P  0.03). The severity of
illness was similar between the two groups, while patients in the FEP-VAN group had
higher baseline creatinine clearance (CLCR) values than patients in the TZP-VAN group
(101 ml/min [interquartile range {IQR}, 77 to 133 ml/min] versus 97 ml/min [IQR, 74 to
125 ml/min], P  0.01). Significant differences in nephrotoxic exposures existed be-
FIG 1 Patient selection diagram. CLCR, creatinine clearance; FEP, cefepime; OSH, outside hospital; TZP,
piperacillin-tazobactam; VAN, vancomycin.
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tween the two groups (Table 1). The median number of nephrotoxic risk factors in each
group was 1 (IQR, 0 to 2, P  0.2); however, the FEP-VAN group had more patients with
4 risk factors (7.8% versus 3.8% in the TZP-VAN group, P  0.0003). Exposure to
contrast dye was more frequent in the FEP-VAN group (58.3% versus 45.3% in the
TZP-VAN group, P  0.0001). Among patients who had VAN concentrations obtained,
no significant difference in VAN exposure was found. However, the FEP-VAN group had
statistically higher average daily VAN doses than the TZP-VAN group. The numbers of
days of antibiotic therapy were similar between the two groups; however, due to the
large sample size and statistical power, the P values are reported to be significant.
TABLE 1 Patient demographic and clinical characteristicsa
Characteristic
Unmatched cohort Matched cohort
TZP-VAN
(n  3,605)
FEP-VAN
(n  588) P value
TZP-VAN
(n  1,633)
FEP-VAN
(n  578) P value
Mean  SD age (yr) 51.5  16.0 49.4  17.0 0.006 49.7  15.7 49.4  17 0.7
No. (%) of male patients 2,177 (60.4) 326 (55.4) 0.03 905 (55.4) 323 (55.9) 0.9
Median (IQR) CCI 3 (1–6) 3 (1–5) 0.2 3 (1–5) 3 (1–5) 1
Median (IQR) baseline CLCR (ml/min) 97 (74–125) 101 (77–132) 0.01 100 (77–126) 101 (77–132) 0.4
No. (%) of patients with:
Hypotension 946 (26.2) 190 (32.3) 0.002 479 (29.3) 186 (32.2) 0.2
Dehydration 220 (6.1) 36 (6.1) 1 98 (6.0) 34 (5.9) 1
Nephrotoxic drug exposure 2,190 (60.7) 349 (59.4) 0.5 939 (57.5) 340 (58.8) 0.6
ACEI/ARB 841 (23.3) 139 (23.6) 0.9 370 (22.7) 135 (23.4) 0.8
No. (%) of patients treated with or
exposed to:
Acyclovir 70 (1.9) 33 (5.6) 0.0001 28 (1.7) 29 (5.0) 0.0001
An aminoglycoside 473 (13.1) 101 (17.2) 0.01 209 (12.8) 98 (17.0) 0.02
Amphotericin B 63 (1.7) 16 (2.7) 0.1 27 (1.7) 15 (2.6) 0.2
A calcineurin inhibitor 114 (3.2) 19 (3.2) 1 35 (2.1) 19 (3.3) 0.2
Contrast dye 1,632 (45.3) 343 (58.3) 0.0001 921 (56.4) 336 (58.1) 0.5
Foscarnet 9 (0.2) 1 (0.2) 1 3 (0.2) 1 (0.2) 1
A loop diuretic 1,121 (31.1) 166 (28.2) 0.2 496 (30.4) 160 (27.7) 0.2
An NSAID 547 (15.2) 88 (15.0) 0.9 242 (14.8) 83 (14.4) 0.8
Sulfonamide 66 (1.8) 9 (1.5) 0.7 27 (1.7) 9 (1.6) 1
Tenofovir 21 (0.6) 4 (0.7) 0.8 8 (0.5) 4 (0.7) 0.5
No. (%) of patients with the
following no. of risk factors:
0.0003 0.3
0 1,132 (31.4) 177 (30.1) 531 (32.5) 177 (30.6)
1 1,163 (32.3) 190 (32.3) 528 (32.3) 187 (32.4)
2 795 (22.1) 113 (19.2) 335 (20.5) 113 (19.6)
3 379 (10.5) 62 (10.5) 160 (10.4) 60 (10.4)
4 136 (3.8) 46 (7.8) 79 (7.1) 41 (7.1)
Median (IQR) VAN dose (mg/day) 2,000 (1,500–2,500) 2,083 (1,600–2,737) 0.0001 2,000 (1,500–2,500) 2,083 (1,600–2,700) 0.002
No. (%) of patients with a daily VAN
dose of 4,000 mg
39 (1.1) 16 (2.7) 0.002 18 (1.1) 16 (2.8) 0.009
No. (%) of patients with the
following maximum VAN
trough concn (g/ml):
0.3 0.7
10 438 (20.8) 77 (21.1) 213 (21.8) 76 (21.1)
10–15 507 (24.1) 100 (27.4) 231 (23.7) 98 (27.2)
15–20 521 (24.8) 88 (24.1) 239 (24.9) 87 (24.2)
20 639 (30.4) 100 (27.4) 293 (30.0) 99 (27.5)
No. of days of antibiotic therapyc
Total 5 (4–8) 5 (4–8) 0.05 5 (4–8) 5 (4–8) 0.4
Combination therapy 3 (3–5) 4 (3–6) 0.001 4 (3–5) 4 (3–6) 0.008
FEP or TZP therapy 5 (3–7) 5 (3–7) 0.8 5 (3–7) 5 (3–7) 0.2
VAN therapy 4 (3–6) 4 (3–7) 0.0001 4 (3–6) 4 (3–7) 0.0001
aACEI, angiotensin-converting enzyme inhibitor; ARB, angiotensin receptor blocker; CCI, Charlson comorbidity index; CLCR, creatinine clearance; FEP, cefepime; IQR,
interquartile range; NSAID, nonsteroidal anti-inflammatory drug; TZP, piperacillin-tazobactam; VAN, vancomycin.
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AKI incidence was significantly higher in patients receiving TZP-VAN than in patients
receiving FEP-VAN (21.4% versus 12.6%, P  0.0001). Classifications of risk (11.7% for
the VAN-TZP group versus 7.5% for the VAN-FEP group, P  0.003) and injury (6.8% for
the VAN-TZP group versus 3.6% for the VAN-FEP group, P  0.004) were more common
in the TZP-VAN group than the VAN-FEP group. The failure classification was not
significantly different between the two groups (Table 2).
Following matching, baseline covariates were well balanced, with the remaining
imbalances being present in acyclovir exposure, aminoglycoside exposure, and average
daily VAN dose (Table 1). AKI remained more common in the TZP-VAN group (21.4% for
the TZP-VAN group versus 12.5% for the VAN-FEP group, P  0.0001), with all levels of
the risk, injury, failure, loss of kidney function, and end-stage kidney disease (RIFLE)
criteria being more common in the TZP-VAN group than the FEP-VAN group (Table 2).
FEP-VAN treatment was associated with an average treatment effect of a 10.1% (95%
confidence interval [CI], 7.8 to 12.2%) reduction in AKI incidence compared to that for
the TZP-VAN group.
After controlling for additional confounders present after matching in the multivar-
iate regression analysis (Table 3), TZP-VAN was associated with 2.18 times the odds of
AKI compared to that for FEP-VAN (95% CI, 1.64 to 2.94 times). Other independent risk
factors for AKI included dehydration and exposure to acyclovir, amphotericin B, or loop
diuretics. VAN doses of between 3 and 4 g daily were associated with an increase in the
incidence of AKI (adjusted odds ratio, 1.61; 95% CI, 1.11 to 2.32) compared to that for
VAN doses of 1,000 and 1,500 mg per day. A duration of VAN treatment of at least 7
days was associated with 1.47 times the odds of AKI (95% CI, 1.14 to 1.89 times)
compared to that associated with VAN treatment for less than 7 days. No evidence of
TABLE 2 Incidence of AKI in unmatched and matched cohortsa
Outcome
Unmatched cohort Matched cohort
No. (%) of patients
P value
No. (%) of patients
P value
VAN-TZP
(n  3,605)
VAN-FEP
(n  588)
VAN-TZP
(n  1,633)
VAN-FEP
(n  578)
Any AKI 771 (21.4) 74 (12.6) 0.0001 349 (21.4) 72 (12.5) 0.0001
Risk 422 (11.7) 44 (7.5) 0.003 179 (11.0) 42 (7.3) 0.01
Injury 244 (6.8) 21 (3.6) 0.004 113 (6.9) 21 (3.6) 0.006
Failure 105 (2.9) 9 (1.5) 0.08 57 (3.5) 9 (1.6) 0.03
aFEP, cefepime; TZP, piperacillin-tazobactam; VAN, vancomycin.
TABLE 3 Multivariate regression results in matched cohorta
Covariate and treatment group Adjusted odds ratio CI P value
TZP-VAN Reference Reference Reference
FEP-VAN 2.18 1.64–2.94 0.001
VAN dose (mg/day)
1,000 0.53 0.16–1.39 0.3
1,000–1,499 1.01 0.72–1.42 0.9
1,500–1,999 Reference Reference Reference
2,000–2,499 1.08 0.79–1.48 0.6
2,500–2,999 1.16 0.81–1.65 0.4
3,000–3,999 1.61 1.11–2.32 0.01
4,000 1.3 0.5–3.05 0.6
Duration of VAN therapy of 7 days 1.47 1.14–1.89 0.003
Acyclovir exposure 2.22 1.17–4.07 0.01
Amphotericin B exposure 2.25 1.14–4.41 0.02
Loop diuretic exposure 2.78 2.22–3.50 0.001
Calcineurin inhibitor exposure 1.62 0.85–2.98 0.1
Dehydration exposure 1.81 1.18–2.72 0.005
aFEP, cefepime; TZP, piperacillin-tazobactam; VAN, vancomycin.
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overfitting was found (Hosmer-Lemeshow P value  0.53), and the model was ade-
quately predictive with a c-statistic of 0.7.
The results of analyses of secondary objectives are summarized in Table 4. There
were no significant differences in the length of stay or mortality. AKI occurred earlier in
TZP-VAN-treated patients in both cohorts. The most common TZP dosing regimen in
the TZP-VAN group was 3.375 g every 6 h (55.6%), with 4.5 g every 6 h being the second
most common regimen (30.4%). AKI incidence was significantly higher in patients
receiving TZP at 4.5 g every 6 h than in patients receiving TZP at 3.375 g every 6 h
(24.3% versus 20.1%, P  0.008) but was significant for risk only when stratified on the
basis of the RIFLE criteria. The most common FEP regimen was 2 g every 8 h (64.8%),
with 2 g every 12 h being the second most common regimen (23.8%). There was no
difference in the incidence of AKI between patients receiving the highest FEP dosing
regimen and patients receiving all other dosing regimens (13.4% versus 11.1%, P  0.5).
DISCUSSION
In this retrospective review of a large cohort of patients receiving VAN-TZP or
VAN-FEP, we found that the incidence of AKI was significantly higher in patients
receiving VAN and TZP concomitantly. To our knowledge, this is the largest study to
date to examine the difference in AKI incidence among patients treated with VAN and
FEP or PTZ. We found the AKI rate in patients treated with VAN-TZP to be 21.4%,
whereas the range of the incidence found in the current literature is 9.5 to 34.8% (8–16).
The AKI incidence in the VAN-FEP group was similar to previous reports of 12.5% (9, 10).
Of note, the AKI incidence in the VAN-FEP group in our study was significantly lower
than that in the study of Hammond et al. (11) (12.5 versus 28.8%), likely due to the
dissimilar patient populations evaluated.
In a 2014 review of 139 diabetic patients with osteomyelitis, VAN-TZP was associated
with a 29.3% incidence of acute renal failure (defined as an increase in the serum
creatinine concentration of 0.5 mg/dl or a 50% increase in the serum creatinine
concentration from that at the baseline), whereas the incidence was 13.3% in the
VAN-FEP group (P  0.099) (9). Gomes and colleagues (2014) conducted a retrospective
review of 224 patients receiving the combination of VAN and TZP or FEP (10). In
univariate analysis, VAN-TZP was associated with an AKI incidence of 34.8%, whereas
the incidence was 12.5% for VAN-FEP (P  0.0001). Additionally, they found that TZP
was an independent predictor of AKI in multiple logistic regression modeling. Finally,
in a review of 122 critically ill patients, Hammond et al. found no difference in AKI
incidence among patients treated with VAN-TZP and VAN-FEP (32.7 versus 28.8%, P 
0.647) (11).
Small sample sizes and a lack of statistical power severely limit the application of the
findings from the previous studies. In addition, aside from the study of Gomes et al.
(10), confounding was not adequately addressed in the studies, further limiting their
application. Our study attempted to rectify these issues by including a larger number
of patients (4,193 in the present study versus 485 in the previous studies combined)
(9–11) and utilizing a propensity score matching algorithm to control for confounders.
The difference in AKI incidence was maintained after controlling for confounders,
suggesting that the use of TZP is associated with increasing rates of AKI compared to
those achieved with the use of FEP when the drugs are combined with VAN.
TABLE 4 Secondary endpointsa
Characteristic
Unmatched cohort Matched cohort
VAN-TZP
(n  3,605)
VAN-FEP
(n  588) P value
VAN-TZP
(n  1,633)
VAN-FEP
(n  578) P value
Median (IQR) time (days) to AKI 5 (3–9) 8 (4–16.8) 0.0006 5 (3–9) 8 (4–17) 0.0004
Median (IQR) hospital length of stay (days) 8 (4–15) 8 (4–17) 0.08 8 (4–15) 8 (5–17) 0.9
No. (%) of patients with in-hospital mortality 276 (7.7) 53 (9.0) 0.3 113 (6.9) 53 (9.2) 0.09
aFEP, cefepime; IQR, interquartile range; TZP, piperacillin-tazobactam; VAN, vancomycin.
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The level of vancomycin exposure was statistically significantly different in both the
unmatched and matched cohorts; however, the difference between the median daily
vancomycin doses is likely clinically irrelevant. To control for the statistical imbalance in
the results for doses of greater than 4,000 mg per day, we included vancomycin dose
in the multivariate regression analysis and found that vancomycin dose is largely
uncorrelated with AKI incidence, with the exception of doses of between 3,000 and
3,999 mg per day. Additionally, we found that a duration of vancomycin therapy of
greater than 7 days was associated with higher rates of AKI, independent of treatment
group. This may be related to the overall vancomycin exposure and warrants further
study. However, when an interaction term between vancomycin dose and a duration of
therapy of greater than 7 days was included in the multivariate logistic regression
model, no significant interaction was found. Vancomycin trough concentrations were
analyzed, but no significant difference between groups was found and no association
with AKI was found. This may be because trough concentrations were not obtained for
many patients; however, there were no significant differences in the number of patients
for whom trough concentrations were obtained between the TZP-VAN and FEP-VAN
groups in both the unmatched and matched cohorts.
Among our secondary outcomes, there was a numerically higher rate of in-hospital
mortality among patients in the FEP-VAN group, but this did not reach statistical
significance. This finding warrants further study; however, FEP-VAN-treated patients
had numerically higher rates of hypotension, which may indicate higher rates of acute
illness not captured by surrogate variables and a predisposition for the patients to
experience mortality.
We found several factors, aside from treatment group, that were independently
associated with AKI incidence. This emphasizes that kidney injury is multifactorial.
Additionally, the use of other nephrotoxic agents, such as loop diuretics in patients with
uncontrolled heart failure, may indicate underlying conditions not captured through
our data analysis that may increase the risk of AKI independently of antibiotic selection.
This study has several limitations which must be addressed. Primarily, due to the
retrospective nature of this analysis, the demonstration of causality is difficult. However,
several mechanisms to make the investigation more rigorous were applied, such as
propensity score matching. In addition, rather than using parameter estimates from
matched cohorts, counterfactual simulations were utilized to predict the average
treatment effect on AKI incidence between groups. We employed a rigorous study
design that controlled for major confounders of AKI, such as concomitant nephrotoxic
exposure, hypotension, and previous renal disease. The nephrotoxic potential of the
agents was assumed to be equal, but this is not necessarily true. Additionally, the binary
representation of nephrotoxic exposure does not describe the amount of the agent
received; as such, our estimations of the odds of AKI may be artificially elevated. Finally,
data were collected retrospectively from the electronic medical record and are subject
to inaccuracies documented in that record; however, any bias introduced should be
nondifferential.
In conclusion, in this large retrospective study, we found that the AKI incidence
among patients who were treated with a combination of piperacillin-tazobactam and
vancomycin was significantly higher than that among patients who were treated with
cefepime and vancomycin. This finding remained after propensity score matching and
after controlling for remaining imbalances in covariates. A mechanism for the increase
in AKI incidence among patients treated with piperacillin-tazobactam compared to that
among patients treated with cefepime has not been proposed. Further animal and
human studies are warranted to elucidate this mechanism.
MATERIALS AND METHODS
Study design and setting. This was a single-center, retrospective matched cohort study of patients
admitted to the University of Kentucky HealthCare Medical Center (UKMC) between 1 September 2010
and 1 September 2014. This study was reviewed and approved by the University of Kentucky Institutional
Review Board.
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Patients received either the combination TZP-VAN or the combination FEP-VAN. VAN was dosed
according to institutional policy (17). Serum VAN concentrations were monitored by pharmacists, and
dosage adjustments were made as clinically appropriate.
Data source. Patient data were collected from the University of Kentucky Center for Clinical and
Translational Science Enterprise Data Trust (EDT). EDT contains clinical data from the inpatient population
of UKMC from 2006 to the present. The data stored in EDT include demographics, financial classification
(Medicare, Medicaid, private insurance), provider-level detail (service line), medical diagnosis (Interna-
tional Classification of Diseases 9 [ICD-9] codes), medical procedures (Current Procedural Terminology
[CPT] codes), lab tests and results, medication administration details, visit details (age, length of stay,
etc.), and vital signs.
Patient selection. Patients were included if they were 18 years of age or older, hospitalized at UKMC
between 1 September 2010 and 1 September 2014, and received either of the studied combinations for
a minimum of 48 h in which therapy with the antibiotics in the combination overlapped for at least 48
h. Patients were excluded if they had a history of chronic kidney disease (stage 3 or higher, via ICD-9
code) or structural kidney disease, required dialysis, had experienced AKI prior to antibiotic administra-
tion, experienced AKI within 48 h of therapy initiation or more than 7 days after the last dose of
antibiotics, or had underlying renal dysfunction (defined as an initial creatinine clearance of 30 ml/min)
at the time of antibiotic initiation. Patients were also excluded from the study if they were pregnant, were
diagnosed with cystic fibrosis, or were transferred from another hospital. Patients were followed
throughout their stay until the time of discharge.
Data collection. Data collected for each patient included demographic data, visit details (length of
stay, admitting and primary diagnosis codes), the severity of underlying illness as defined by the Charlson
comorbidity index (CCI) (18), all serum creatinine levels determined per visit, receipt of other nephrotoxic
agents (listed in Table 1), and any receipt of intravenous contrast agents. The initial serum creatinine
concentration was used as the patient’s baseline. Hypotension was defined as a diagnosis of hypotension
by ICD-9 coding, a mean arterial pressure of less than 60 mm Hg, or the use of vasopressor or inotrope
therapy to maintain adequate perfusion. Contrast exposure was defined as exposure to an imaging
procedure in which contrast is indicated via Healthcare Common Procedure Coding System (HCPCS)
codes. The doses and dosing schedules of the studied antibiotics and all vancomycin serum concentra-
tions were obtained. The number of days of antibiotic therapy was defined as receipt of at least one dose
of antibiotic per day.
Study outcomes. The primary outcome was the difference in AKI incidence between the group
receiving TZP-VAN and the group receiving FEP-VAN. Secondary outcomes were AKI incidence on the
basis of dosing schemes and duration of therapy, the time to AKI from the time of initiation of therapy,
hospital length of stay, and mortality (defined as in-hospital mortality or transfer to a hospice facility).
Development of AKI was evaluated using risk, injury, failure, loss of kidney function, and end-stage
kidney disease (RIFLE) criteria (19). The RIFLE criteria consist of three severity classes (risk, injury, failure)
and two outcomes classes (loss of kidney function, end-stage kidney disease). Risk was defined as a
decrease in the glomerular filtration rate (GFR) of at least 25%, injury was defined as a decrease in the
GFR of at least 50%, and failure was defined as a decrease in the GFR of 75% or more. The outcomes
classes require a diagnosis based on the duration of renal dysfunction and were not evaluated in this
study. GFR was estimated with the adjusted Cockcroft-Gault equation (20).
Patient matching. Antibiotic indications were unknown, and antibiotic choice was prescriber
specific; therefore, propensity scores for each patient were estimated to control for potential bias.
Patients in the TZP-VAN group were matched three to one with patients in the FEP-VAN group using a
nearest-neighbor propensity score algorithm (21) without replacement and a caliper of 0.2 on the basis
of the following factors: age, gender, CCI, hypotension exposure, risk factor group (defined by the
number of nephrotoxic exposures, i.e., 0, 1, 2, 3, and 4), baseline creatinine clearance, and receipt of
intravenous (i.v.) contrast dye. Additionally, patients were matched exactly on the basis of gender,
hypotension exposure, risk factor group, and i.v. contrast dye administration.
Statistical analysis. Characteristics between groups were described using basic descriptive statistics,
with continuous variables being compared by Student’s t test or the Wilcoxon rank-sum test and
categorical variables being compared by the chi-square test or Fisher’s exact test, as appropriate. The
average treatment effect was calculated by taking the average difference in the incidence of AKI in 1,000
counterfactual simulations after fitting of logistic regression models based on each treatment group to
the opposite population (22, 23). Following propensity score matching, simple logistic regression was
performed on all variables. In addition to the remaining covariate imbalances in the matched cohort, the
variables with significant associations with AKI in univariate regressions were incorporated into the
multivariate logistic regression. All statistical analyses were completed with the RStudio (v0.98) program
running R (v3.1.2) software (R Foundation for Statistical Computing, Vienna, Austria) (24, 25). The model
fit was assessed by use of the standardized Hosmer-Lemeshow test (26) and the c-statistic. All tests were
two-tailed, and significance was defined at an alpha value of 0.05.
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Table 3, the first two cells in the “Covariate and treatment group” column were
switched. Table 3 should appear as shown below.
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TABLE 3 Multivariate regression results in matched cohorta
Covariate and treatment group Odds ratio CI P value
FEP-VAN Reference Reference Reference
TZP-VAN 2.18 1.64–2.94 0.001
VAN dose (mg/day)
1,000 0.53 0.16–1.39 0.3
1,000–1,499 1.01 0.72–1.42 0.9
1,500–1,999 Reference Reference Reference
2,000–2,499 1.08 0.79–1.48 0.6
2,500–2,999 1.16 0.81–1.65 0.4
3,000–3,999 1.61 1.11–2.32 0.01
4,000 1.3 0.5–3.05 0.6
Duration of VAN therapy of 7 days 1.47 1.14–1.89 0.003
Acyclovir exposure 2.22 1.17–4.07 0.01
Amphotericin B exposure 2.25 1.14–4.41 0.02
Loop diuretic exposure 2.78 2.22–3.50 0.001
Calcineurin inhibitor exposure 1.62 0.85–2.98 0.1
Dehydration exposure 1.81 1.18–2.72 0.005
aFEP, cefepime; TZP, piperacillin-tazobactam; VAN, vancomycin.
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